These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 9735134

  • 1. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies.
    Demeure MJ, Somberg LB.
    Surg Oncol Clin N Am; 1998 Oct; 7(4):791-805. PubMed ID: 9735134
    [Abstract] [Full Text] [Related]

  • 2. Adjunctive treatment of adrenocortical carcinoma.
    Terzolo M, Berruti A.
    Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):221-6. PubMed ID: 18438168
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Adjuvant mitotane in adrenocortical carcinoma.
    Lee JE.
    N Engl J Med; 2007 Sep 20; 357(12):1258; author reply 1259. PubMed ID: 17891836
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Adjuvant mitotane treatment for adrenocortical carcinoma.
    Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A.
    N Engl J Med; 2007 Jun 07; 356(23):2372-80. PubMed ID: 17554118
    [Abstract] [Full Text] [Related]

  • 12. [Malignant adrenocortical tumors. Apropos of 9 cases].
    Benchekroun A, Benslimane L, Iken A, Chefchaouni MC, Faik M, Marzouk A.
    Ann Urol (Paris); 1996 Jun 07; 30(1):33-7. PubMed ID: 8712758
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrump D, Bartlett D, Choyke P, Robey R, Hung E, Steinberg SM, Bates S, Fojo T.
    Cancer; 2002 May 01; 94(9):2333-43. PubMed ID: 12015757
    [Abstract] [Full Text] [Related]

  • 15. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.
    Veytsman I, Nieman L, Fojo T.
    J Clin Oncol; 2009 Sep 20; 27(27):4619-29. PubMed ID: 19667279
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
    Abdel-Aziz TE, Rajeev P, Sadler G, Weaver A, Mihai R.
    World J Surg; 2015 May 20; 39(5):1268-73. PubMed ID: 25526921
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
    Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH, Crawford ED.
    Cancer; 2000 Mar 01; 88(5):1159-65. PubMed ID: 10699907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.